Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H20N2O2 |
Molecular Weight | 212.2887 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
InChI
InChIKey=MSYKRHVOOPPJKU-BDAKNGLRSA-N
InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
Brivaracetam (UCB 34714, trade name Briviact), the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam, but with 20-fold greater affinity. There is some evidence that racetams including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis. They may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1998 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19914041 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BRIVIACT Approved UseBRIVIACT is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy Launch Date2016 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
55.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
90.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
104.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
27.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
56 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18341673 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRIVARACETAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
80% |
unknown, unknown |
BRIVARACETAM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1400 mg single, oral Highest studied dose|MID |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Other AEs: Somnolence, Blurred vision... Other AEs: Somnolence (severe, 2 patients) Sources: Blurred vision (1 patient) Dizziness (2 patients) Agitation (1 patient) Bradyphrenia (1 patient) Disorientation (1 patient) Euphoric mood (1 patient) |
1000 mg single, oral MTD |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Other AEs: Somnolence, Blurred vision... Other AEs: Somnolence (2 patients) Sources: Blurred vision (1 patient) Dizziness (3 patients) Agitation (1 patient) Bradyphrenia (1 patient) Disorientation (1 patient) Euphoric mood (1 patient) |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 37.2 years n = 2186 Health Status: unhealthy Age Group: 37.2 years Sex: M+F Population Size: 2186 Sources: |
Disc. AE: Convulsion, Somnolence... AEs leading to discontinuation/dose reduction: Convulsion (1.4%) Sources: Somnolence (0.7%) Depression (0.6%) Dizziness (0.6%) Fatigue (0.5%) Suicidal ideation (0.5%) Suicide attempt (0.5%) |
800 mg 1 times / day steady, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: Page: p. 28 |
healthy, 64.1 years n = 7 Health Status: healthy Age Group: 64.1 years Population Size: 7 Sources: Page: p. 28 |
Other AEs: Somnolence, Dizziness... Other AEs: Somnolence (57.1%) Sources: Page: p. 28Dizziness (42.9%) |
2 mg/kg 2 times / day steady, oral Highest studied dose Dose: 2 mg/kg, 2 times / day Route: oral Route: steady Dose: 2 mg/kg, 2 times / day Sources: |
unhealthy, <8 years Health Status: unhealthy Condition: generalized epilepsy Age Group: <8 years Sex: M+F Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | 1 patient | 1400 mg single, oral Highest studied dose|MID |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Blurred vision | 1 patient | 1400 mg single, oral Highest studied dose|MID |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Bradyphrenia | 1 patient | 1400 mg single, oral Highest studied dose|MID |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Disorientation | 1 patient | 1400 mg single, oral Highest studied dose|MID |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Euphoric mood | 1 patient | 1400 mg single, oral Highest studied dose|MID |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Dizziness | 2 patients | 1400 mg single, oral Highest studied dose|MID |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Somnolence | severe, 2 patients | 1400 mg single, oral Highest studied dose|MID |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Agitation | 1 patient | 1000 mg single, oral MTD |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Blurred vision | 1 patient | 1000 mg single, oral MTD |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Bradyphrenia | 1 patient | 1000 mg single, oral MTD |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Disorientation | 1 patient | 1000 mg single, oral MTD |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Euphoric mood | 1 patient | 1000 mg single, oral MTD |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Somnolence | 2 patients | 1000 mg single, oral MTD |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Dizziness | 3 patients | 1000 mg single, oral MTD |
healthy, 18-55 years n = 6 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 6 Sources: |
Fatigue | 0.5% Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 37.2 years n = 2186 Health Status: unhealthy Age Group: 37.2 years Sex: M+F Population Size: 2186 Sources: |
Suicidal ideation | 0.5% Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 37.2 years n = 2186 Health Status: unhealthy Age Group: 37.2 years Sex: M+F Population Size: 2186 Sources: |
Suicide attempt | 0.5% Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 37.2 years n = 2186 Health Status: unhealthy Age Group: 37.2 years Sex: M+F Population Size: 2186 Sources: |
Depression | 0.6% Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 37.2 years n = 2186 Health Status: unhealthy Age Group: 37.2 years Sex: M+F Population Size: 2186 Sources: |
Dizziness | 0.6% Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 37.2 years n = 2186 Health Status: unhealthy Age Group: 37.2 years Sex: M+F Population Size: 2186 Sources: |
Somnolence | 0.7% Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 37.2 years n = 2186 Health Status: unhealthy Age Group: 37.2 years Sex: M+F Population Size: 2186 Sources: |
Convulsion | 1.4% Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 37.2 years n = 2186 Health Status: unhealthy Age Group: 37.2 years Sex: M+F Population Size: 2186 Sources: |
Dizziness | 42.9% | 800 mg 1 times / day steady, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: Page: p. 28 |
healthy, 64.1 years n = 7 Health Status: healthy Age Group: 64.1 years Population Size: 7 Sources: Page: p. 28 |
Somnolence | 57.1% | 800 mg 1 times / day steady, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: Page: p. 28 |
healthy, 64.1 years n = 7 Health Status: healthy Age Group: 64.1 years Population Size: 7 Sources: Page: p. 28 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 541 uM] | ||||
no [IC50 740 uM] | ||||
no [Inhibition 200 uM] | ||||
no [Inhibition 650 uM] | ||||
no [Inhibition 650 uM] | ||||
no [Inhibition 650 uM] | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
yes [Km 70 uM] | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. | 2004 Jan 29 |
|
Brivaracetam UCB. | 2005 Jul |
|
Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. | 2007 |
|
Gateways to clinical trials. | 2007 Dec |
|
Brivaracetam (UCB 34714). | 2007 Jan |
|
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). | 2007 Jan |
|
Pharmacological management of epilepsy: recent advances and future prospects. | 2008 |
|
Gateways to clinical trials. | 2008 Apr |
|
Effect of brivaracetam on cardiac repolarisation--a thorough QT study. | 2008 Aug |
|
Brivaracetam: a rational drug discovery success story. | 2008 Aug |
|
Treatment of Lennox-Gastaut syndrome: overview and recent findings. | 2008 Dec |
|
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. | 2008 Dec |
|
Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. | 2008 Dec 28 |
|
Modifications of antiepileptic drugs for improved tolerability and efficacy. | 2008 Feb 14 |
|
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. | 2008 Jan |
|
New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. | 2008 Jul |
|
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. | 2008 Jul |
|
Gateways to clinical trials. | 2008 Mar |
|
Brivaracetam: a new drug in development for epilepsy and neuropathic pain. | 2008 Mar |
|
SVOP is a nucleotide binding protein. | 2009 |
|
What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. | 2009 Dec |
|
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). | 2009 Jan |
|
Brivaracetam inhibits spreading depression in rat neocortical slices in vitro. | 2009 Jul |
|
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. | 2009 Mar-Apr |
|
Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. | 2010 Apr |
|
Gateways to clinical trials. | 2010 Apr |
|
Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. | 2010 Aug 10 |
|
New drugs for pediatric epilepsy. | 2010 Dec |
|
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). | 2010 Dec |
|
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. | 2010 Feb 12 |
|
Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. | 2010 Jan |
|
Gateways to clinical trials. | 2010 Mar |
|
Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. | 2010 Mar |
|
Antiepileptic drug interactions - principles and clinical implications. | 2010 Sep |
|
Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats. | 2010 Sep |
|
Emerging drugs for partial onset seizures. | 2010 Sep |
Sample Use Guides
The recommended starting dosage is 50 mg twice daily (100 mg per day). Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day). BRIVIACT (brivaracetam) injection may be used when oral administration is temporarily not feasible. BRIVIACT injection should be administered at the same dosage and same frequency as BRIVIACT tablets and oral solution.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19914041
Brivaracetam (BRV) is able to modulate the voltage-activated Na(+) inflow in cortical neurons. Voltage-activated Na(+) currents were recorded by whole-cell patch-clamp on neuronal somas of rat neocortical neurons, grown in dissociated cell culture for up to 12 days. BRV, dissolved at the desired final concentration (between 0.2 microM and 1 mM) was applied by a multi-barrel pipette system near the soma of the recorded neuron. BRV produced a concentration-dependent inhibition of voltage-dependent Na(+) currents with IC(50) values of 41 microM at the holding potential of -100 mV, and of 6.5 microM at the holding potential of -60 mV. The voltage-dependence of activation and the kinetics of fast inactivation were not modified in the presence of BRV (30 microM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/05/315
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
||
|
WHO-ATC |
N03AX23
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
||
|
FDA ORPHAN DRUG |
207305
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
||
|
FDA ORPHAN DRUG |
724019
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
||
|
FDA ORPHAN DRUG |
711119
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BRIVARACETAM
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
5068
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
9837243
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
133013
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
DTXSID00905081
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL607400
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
8642
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
N0000192345
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | Epoxide Hydrolase Inhibitors [MoA] | ||
|
U863JGG2IA
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
C65270
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
SUB25397
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
DB05541
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
Brivaracetam
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
QQ-109
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
1739745
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
U863JGG2IA
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
357336-20-0
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
100000089410
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | |||
|
m2654
Created by
admin on Fri Dec 15 15:48:27 GMT 2023 , Edited by admin on Fri Dec 15 15:48:27 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)